Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
复制标题

DOI：
--
复制
发表时间：
2002-07
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
通讯作者：
T. Fehm;A. Sagalowsky;E. Clifford;P. Beitsch;H. Saboorian;D. Euhus;S. Meng;L. Morrison;T. Tucker
T. Fehm;A. Sagalowsky;E. Clifford;P. Beitsch;H. Saboorian;D. Euhus;S. Meng;L. Morrison;T. Tucker
中科院分区：
其他
文献类型：
--
作者：
T. Fehm;A. Sagalowsky;E. Clifford;P. Beitsch;H. Saboorian;D. Euhus;S. Meng;L. Morrison;T. Tucker

文献摘要

被引文献

相似文献

目的 对癌症患者的循环上皮细胞 (CEC) 进行了大量研究，并且遗传异常已得到充分记录。然而，除了结直肠癌中的一个例外，目前还没有将 CEC 中的遗传异常与原发肿瘤相匹配的报道。本研究的目的是确定 (a) 患者（包括早期肿瘤患者）的 CEC 是否为异体，以及 (b) 它们的异体模式是否与原发肿瘤的一致，表明存在共同克隆性。实验设计 使用单克隆抗细胞角蛋白抗体通过免疫荧光染色鉴定了 31 名癌症患者的 CEC。他们的 CEC 通过双色或三色荧光原位杂交，通过染色体 1、3、4、7、8、11 或 17 的计数 DNA 探针进行分析。 31 名患者中的 17 名获得了原发性肿瘤组织的接触标本，并与用于 CEC 基因分型的同一组探针杂交。结果每位患者的 CEC 数量范围为 1-92 个细胞/细胞离心涂片。 31 名患者中有 25 名的 CEC 至少显示其中一种探针的拷贝数异常。 13 名患有非体 CEC 的患者的原发肿瘤的接触制剂已可用。解剖学模式与 10 名患者的原发肿瘤中的克隆相匹配。结论 我们的结论是，乳腺癌、肾癌、前列腺癌和结肠癌患者中的绝大多数 CEC 都是非异体的，并且源自原发肿瘤。
PURPOSE Numerous studies of circulating epithelial cells (CECs)have been described in cancer patients, and genetic abnormalities have been well documented. However, with one exception in colorectal cancer, there has been no report of matching the genetic abnormalities in the CECs with the primary tumor. The purpose of this investigation was to determine (a) whether CECs in patients including those with early tumors are aneusomic and (b) whether their aneusomic patterns match those from the primary tumor, indicating common clonality. EXPERIMENTAL DESIGN Thirty-one cancer patients had CECs identified by immunofluorescence staining using a monoclonal anti-cytokeratin antibody. Their CECs were analyzed by enumerator DNA probes for chromosomes 1, 3, 4, 7, 8, 11, or 17 by dual or tricolor fluorescence in situ hybridization. Touch preparations of the primary tumor tissue were available from 17 of 31 patients and hybridized with the same set of probes used to genotype the CECs. RESULTS The number of CECs from each patient ranged from 1-92 cells/cytospin. CECs showed abnormal copy numbers for at least one of the probes in 25 of 31 patients. Touch preparations from the primary tumors of 13 patients with aneusomic CECs were available. The pattern of aneusomy matched a clone in the primary tumor in 10 patients. CONCLUSIONS We conclude that the vast majority of CECs in breast, kidney, prostate, and colon cancer patients are aneusomic and derived from the primary tumor.